Intriptyline is a dibenzocycloheptene derivative and mixed monoamine reuptake inhibitor patented by Laboratoires du Docteur Jacques Auclair as tricyclic antidepressant.

Dimelazine is a sedative, antihistaminic agent.

Clociguanil (BRL 50216, WR 38839) is an antimalarial compound, a derivative of N-benzyloxydihydrotriazine, developed by Beecham Pharmaceuticals. Mode of action studies indicated that clociguanil is a dihydrofolate reductase inhibitor of Plasmodium and is capable of marked potentiation with a selected sulphonamide against both the sensitive N strain and the cycloguanil-resistant B line of P. berghei. A combination of clociguanil and sulphadiazine prevented the development of parasitemia caused by P. falciparum in humans. The subsequent development of clociguanil was discontinued because of a relatively short half-life in man and lack of suppression of pre-erythrocytic schizogony of a strain of P. falciparum resistant to chloroquine, pyrimethamine, and proguanil.

Darotropium is a muscarinic acetylcholine antagonist, developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Darotropium in combination with salmeterol was investigated in phase 2 clinical trial in COPD patients. The addition of darotropium to salmeterol in partially reversible COPD patients resulted in greater bronchodilation than salmeterol or tiotropium alone and was well tolerated. In a clinical trial of darotropium as monotherapy, all doses of the drug were well tolerated and demonstrated bronchodilatory activity. However, the rapid onset of bronchodilation was not sustained over 24 h, and GSK has discontinued the development of darotropium in favor of GSK573719, which has more favorable pharmacokinetics.

Omocianine was developed as an enhancer of fluorescence optical mammography allowed better detection of more superficially located lesions. It was shown that the lowest doses of omocianine performed best in lesion detection. Diffuse optical tomography using a low-dose fluorescent agent is feasible and safe for breast cancer visualization in patients. This compound participated in phase I clinical trials in Germany and in the Netherlands, however, these studies were discontinued.

Cortisuzol is a glucocorticoid corticosteroid, discovered by the French company Roussel Uclaf, and claimed to have anti-inflammatory activity in a number of clinical case reports.

Motexafin is texaphyrin patented by pharmaceutical company Pharmacyclics, Inc. as chelating agents useful for the treatment of neoplastic and cardiovascular disease. The MRI-detectable gadolinium complex of motexafin was studied as a redox modulator that selectively targets tumor cells.

Metrenperone, a 5-hydroxytryptamine blocker, is used in veterinary as an antimyopathic agent. Experiments on rabbits have shown that the drug had positive effects on collagen turnover, remodeling, and organization during acute inflammation and fibroplasia.

Fuzlocillin is a penicillin antibiotic. This semisynthetic acylureidopenicillin with antibacterial activity binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Fuzlocillin (furazlocillin), has been shown to be highly specific for the FtsI gene. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing the cell to break down (cell lysis). Among the acylureidopenicillins, furaclocillin exerts increased activity against Escherischia coli, Klebsiella, Proteus and Pseudomonas aeruginosa.